Brief: Spago Nanomedical Q4 Sales SEK 617 Thousand
Feb 06 (Reuters) - Spago Nanomedical Q4 adjusted EPS SEK -0.02. * Q4 operating expenses SEK -10.223 million * Q4 net income SEK -7.83 million
Recent news on Spago Nanomedical AB (publ)
See all newsBrief: Spago Nanomedical Announces Outcome Of Rights Issue
Brief: Spago Nanomedical Resolves On Rights Issue Of About SEK 16 Million
Sweden's Spago Nanomedical Q1 loss narrows
Brief: Spago Nanomedical Q1 Sales SEK 22 Thousand
Brief: Spago Nanomedical Says Tumorad-01 Study Meets Primary Endpoint Of Maximum Tolerated Dose